

## **SR Pharma plc**

### **Extraordinary General Meeting**

**London, 30 March 2007** – SR Pharma plc (the Company) is today posting a circular to shareholders convening an extraordinary general meeting to be held at 10.00 a.m. on 26 April 2007 at Centre Point, 103 New Oxford Street, London WC1A 1DD at which the following resolutions will be proposed :

1. A resolution changing the name of the Company to Silence Therapeutics plc.
2. Resolutions granting the directors authority to issue shares up to a nominal value of £113,065, representing approximately 10 per cent. of the Company's current issued share capital thereby disapplying the normal pre-emption rights of shareholders.

A copy of the circular is available at the Company's website, [www.srpharma.com](http://www.srpharma.com).

- Ends -

Notes to Editors

#### **SR Pharma ([www.srpharma.com](http://www.srpharma.com))**

SR Pharma plc is a European biopharmaceutical company, listed on AIM. The Company has two operating subsidiaries Atugen AG ([www.atugen.com](http://www.atugen.com)) based in Berlin, Germany and Stanford Rook Ltd based in London, UK.

SR Pharma is a leader in RNAi therapeutics, which is a Nobel Prize winning technology that "silences" genes linked to the onset of disease. The Company has developed novel, chemically modified proprietary siRNA molecules ("AtuRNAi"), which have a number of advantages over conventional siRNA molecules including enhanced stability against nuclease degradation. In addition, the Company has developed a proprietary delivery system ("AtuPLEX"), which increases bioavailability, circulation times and functional intracellular uptake of siRNA molecules.

SR Pharma expects to begin the clinical development of its proprietary AtuRNAi therapeutic molecules for systemic cancer indications in 2007. SR Pharma has sublicensed the AtuRNAi compound RTP-801i to Pfizer through its collaboration partner Quark Biotech Inc. for the treatment of Age-related Macular Degeneration (AMD) and a number of other indications. This compound entered the clinic in early 2007. In addition SR Pharma has licensed a further AtuRNAi compound, AKli-5, to Quark Biotech Inc. This compound has been granted an IND for acute kidney injury and is expected to enter the clinic in 2007.

SR Pharma also owns a proprietary Mycobacterium vaccae-based technology and related products. Currently the Company is in discussions with third parties regarding the co-development and out-licensing of these products.

#### **Forward-Looking Statements**

This press release includes forward-looking statements that are subject to risks, uncertainties and other factors. These risks and uncertainties could cause actual results to differ materially from those referred to in the forward-looking statements. All forward-looking statements are based on

information currently available to SR Pharma and SR Pharma assumes no obligation to update any such forward-looking statements.

**Enquiries:**

For further information, please contact the following:

**SR Pharma plc**

+44(0)20 7307 1620

Iain Ross, Chairman

Melvyn Davies, Finance Director

**Citigate Dewe Rogerson**

+44(0)20 7638 9571

David Dible

Yvonne Alexander

**Atugen AG**

+49(0)30 9489 2800

Thomas Christély, Chief Executive Officer

Dr. Klaus Giese, Chief Scientific Officer

**Grant Thornton Corporate Finance**

+44 (0) 20 7383 5100

Gerry Beaney

Colin Aaronson